148 related articles for article (PubMed ID: 2462946)
21. [Interferon and therapy of oncological diseases].
Andzhaparidze OG; Pille ER
Vopr Virusol; 1989; 34(5):517-23. PubMed ID: 2481902
[No Abstract] [Full Text] [Related]
22. In vitro antiproliferative effect of interferon alpha in solid tumors: a potential predictive test.
Fuchsberger N; Kubes M; Kontsek P; Borecký L; Hornák M; Godál A; Silvanová ; Svec J
Neoplasma; 1993; 40(5):293-6. PubMed ID: 8272157
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
24. In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells.
Fridborg H; Nygren P; Dhar S; Csoka K; Kristensen J; Larsson R
J Exp Ther Oncol; 1996 Sep; 1(5):286-95. PubMed ID: 9414416
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
26. Systemic specific active immunotherapy for solid tumors. An overview about cancer vaccinetherapy.
Tagliaferri F; Sirovich I; Stipa F; Valente MG; Pupelis G; Tremiterra S
Recenti Prog Med; 1994 Dec; 85(12):591-6. PubMed ID: 7899685
[TBL] [Abstract][Full Text] [Related]
27. [Possibilities and limits of the use of interferons in the clinic].
Ludwig CU
Schweiz Med Wochenschr; 1989 Nov; 119(44):1539-43. PubMed ID: 2479977
[TBL] [Abstract][Full Text] [Related]
28. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
29. Further experience in testing the sensitivity of human ovarian carcinoma cells to interferon in an in vitro semisolid agar culture system: comparison of solid and ascitic forms of the tumor.
Epstein LB; Shen JT; Abele JS; Reese CC
Prog Clin Biol Res; 1980; 48():277-90. PubMed ID: 6163159
[TBL] [Abstract][Full Text] [Related]
30. Overview of interleukin-2 inhalation therapy.
Huland E; Heinzer H; Huland H; Yung R
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
[TBL] [Abstract][Full Text] [Related]
31. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
32. Clinical trials referral resource. NCI-sponsored trials of interleukin-6 (IL-6).
Cheson BD; Carter CL; Sznol M
Oncology (Williston Park); 1993 Jun; 7(6):43-4. PubMed ID: 8391298
[No Abstract] [Full Text] [Related]
33. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
34. [Management of digestive system carcinoid tumors and carcinoid syndrome].
Mondragón Sánchez RJ; Castillero Pinilla C; Saldívar Moreno C; Oñate Ocaña LF; Ruiz Molina JM; Aiello Crocifoglio V
Rev Gastroenterol Mex; 1998; 63(4):204-10. PubMed ID: 10319670
[TBL] [Abstract][Full Text] [Related]
35. Interferons in the treatment of advanced breast cancer.
Repetto L; Venturino A; Simoni C; Rosso M; Melioli G; Rosso R
J Biol Regul Homeost Agents; 1993; 7(4):109-14. PubMed ID: 7517612
[TBL] [Abstract][Full Text] [Related]
36. [Immunotherapy of malignant diseases].
Dorval T; Michon J; Tartour E; Fridman WH
Bull Cancer; 1995; 82 Suppl 2():127s-138s. PubMed ID: 7542946
[TBL] [Abstract][Full Text] [Related]
37. [Immunotherapy of metastatic renal cell cancer].
Manseck A; Wirth M
Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
[TBL] [Abstract][Full Text] [Related]
38. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
Ulbright TM
Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
[TBL] [Abstract][Full Text] [Related]
39. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
Kadhim SA; Bowlin TL; Waud WR; Angers EG; Bibeau L; DeMuys JM; Bednarski K; Cimpoia A; Attardo G
Cancer Res; 1997 Nov; 57(21):4803-10. PubMed ID: 9354442
[TBL] [Abstract][Full Text] [Related]
40. Pathophysiology of tumor angiogenesis and its relevance in renal cell cancer.
Strohmeyer D
Anticancer Res; 1999; 19(2C):1557-61. PubMed ID: 10365145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
